QC
ACHN

QCM Cayman’s Achillion Pharmaceuticals ACHN Stock Holding History

QCM Cayman’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,115
Closed -$16K – 135
2018
Q4 		$16K Buy
+10,115
New +$28.6K 0.07% 121
2018
Q1 		– Sell
-14,756
Closed -$42K – 206
2017
Q4 		$42K Buy
+14,756
New +$53.6K 0.17% 109
2013
Q4 		– Sell
-11,558
Closed -$35K – 189
2013
Q3 		$35K Buy
+11,558
New +$79.2K 0.02% 169

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QCM Cayman's ACHN Position: Q1 2019 in Review

QCM Cayman sold out of Achillion Pharmaceuticals (ACHN) in Q1 2019, closing a stake of 10,115 shares — an estimated $16K sold.

QCM Cayman first reported a position in ACHN in Q3 2013 and held it in 3 quarters. The position peaked at $42K in Q4 2017. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

  • QCM Cayman reported no remaining Achillion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • QCM Cayman sold 10,115 Achillion Pharmaceuticals shares in Q1 2019, an estimated $16K.
  • QCM Cayman first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • QCM Cayman's Achillion Pharmaceuticals position peaked at $42K in Q4 2017.
  • 110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on QCM Cayman's 13F filing for Q1 2019, filed 13 May 2019.